Actively Recruiting
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer to Assess Tumor ER Expression and Guide Treatment
Led by Tongji Hospital · Updated on 2022-09-15
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer is a common cancer in women, with up to 70% having hormone receptor-positive tumors, mainly estrogen receptor (ER) positive. This research aims to evaluate the use of 18F-Fluoroestradiol (18F-FES), a special imaging tracer that targets estrogen receptors, to measure ER expression in primary and metastatic breast cancer. The study focuses on understanding ER levels to better guide treatment decisions, especially since ER status can vary between original and metastatic tumors. The study uses 18F-FES PET/CT imaging, which specifically detects estrogen receptor-positive tumors with high accuracy. This imaging method may help predict how patients respond to endocrine therapy and assist in selecting patients who may benefit more from hormone treatment versus chemotherapy. Patients undergo PET/CT scans that visualize ER expression in their breast cancer tumors. Participants will have their ER status assessed by 18F-FES PET/CT imaging. Researchers will measure the maximum standardized uptake value (SUVmax) over a five-year period as the main outcome. The study involves consenting adults diagnosed with breast cancer and excludes pregnant women and those with severe conditions that prevent PET examination. This observational study helps improve understanding of breast cancer characteristics and treatment planning.
CONDITIONS
Brief Title
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- More than 18 years old
- Patients with pathologically confirmed breast cancer
- Sign the informed consent form
You will not qualify if you...
- Pregnant women
- Severe underlying diseases that cannot cooperate with PET examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo FES PET/CT imaging to assess estrogen receptor status of breast tumors.
1 imaging visit (in-person)
Duration - Up to 5 years
Participants are monitored over time to observe tumor characteristics and treatment responses based on imaging results.
Follow-up visits as scheduled for up to 5 years
Trial Site Locations
Total: 1 location
1
TongjiHospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Z
ZHU XIAOHUA, DR
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here